US 10392441
IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia
granted A61KA61K2039/505A61K31/395
Quick answer
US patent 10392441 (IL-7R-alpha specific antibodies for treating acute lymphoblastic leukemia) held by UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- UNITED STATES OF AMERICA, AS REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
- Grant date
- Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 32
- CPC classes
- A61K, A61K2039/505, A61K31/395, A61K39/3955, A61K39/39558